keyword
MENU ▼
Read by QxMD icon Read
search

Acosog z0011

keyword
https://www.readbyqxmd.com/read/30197938/is-completion-axillary-lymph-node-dissection-necessary-in-patients-who-are-underrepresented-in-the-acosog-z0011-trial
#1
Brian J Gebhardt, Joel Thomas, Zachary D Horne, Colin E Champ, Daniel J Farrugia, Emilia Diego, Gretchen M Ahrendt, Sushil Beriwal
Purpose: The American College of Surgeons Oncology Group trial Z0011 demonstrated that axillary node dissection (ALND) can be omitted in patients managed with breast conserving surgery and 1 to 2 positive sentinel lymph nodes (SLNs) without adverse effects on locoregional recurrence or disease-free survival (DFS). We investigated patients with breast cancer for whom clinicopathologic features were underrepresented in the Z0011 trial and analyzed radiation therapy treatment patterns and clinical outcomes...
July 2018: Advances in Radiation Oncology
https://www.readbyqxmd.com/read/30138762/reducing-harms-from-treatment-sixteen-years-of-surgery-of-the-axilla-for-screen-detected-breast-cancers-in-italy
#2
Maria Grazia Lazzaretti, Antonio Ponti, Maria Piera Mano, Alessandra Barca, Denise Casella, Alfonso Frigerio, Livia Giordano, Paola Mantellini, Adriana Paduos, Sabina Pitarella, Alessandra Ravaioli, Mario Taffurelli, Mariano Tomatis, Nereo Segnan
OBJECTIVES: Available evidence on axillary surgery has accumulated dramatically in the last two decades in favor of less invasive care. The aim of this paper is to study 16-years trends in the surgical management of the axilla in a large population-based data set of screen-detected breast cancers in Italy and to document at what extent recommendations have been adopted in actual clinical care. MATERIAL AND METHODS: This is a retrospective cohort study documenting the surgical management of the axilla in primary breast cancer patients over time...
August 14, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/30060915/survival-analysis-of-early-stage-breast-cancer-patients-undergoing-axillary-lymph-node-dissection-and-sentinel-lymph-node-dissection
#3
Apoorve Nayyar, Paula D Strassle, Mary R Shen, Jonathan A Black, Kristalyn K Gallagher, Kandace P McGuire
BACKGROUND: The American College of Surgeons Oncology Group (ACOSOG) Z0011 trial demonstrated equivalent survival in early-stage breast cancer (BC) patients receiving either axillary lymph node dissection (ALND) or sentinel lymph node dissection (SLND) alone. However, institutional studies have called into question the generalization of these findings outside of a clinical trial. METHODS: Early-stage BC patients diagnosed in 2013, that received lumpectomy with whole-breast irradiation, and underwent either ALND or SLND alone, in National Cancer Database were included...
July 24, 2018: American Journal of Surgery
https://www.readbyqxmd.com/read/30003237/surgeon-attitudes-toward-the-omission-of-axillary-dissection-in-early-breast-cancer
#4
Monica Morrow, Reshma Jagsi, M Chandler McLeod, Dean Shumway, Steven J Katz
Importance: The American College of Surgeons Oncology Group (ACOSOG) Z0011 study demonstrated the safety of sentinel node biopsy alone in clinically node-negative women with metastases in 1 or 2 sentinel nodes treated with breast conservation. Little is known about surgeon perspectives regarding when axillary lymph node dissection (ALND) can be omitted. Objectives: To determine surgeon acceptance of ACOSOG Z0011 findings, identify characteristics associated with acceptance of ACOSOG Z0011 results, and examine the association between acceptance of the Society of Surgical Oncology and American Society for Radiation Oncology negative margin of no ink on tumor and surgeon preference for ALND...
July 12, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29848724/factors-predictive-of-sentinel-lymph-node-involvement-in-primary-breast-cancer
#5
Wolfram Malter, Martin Hellmich, Mayhar Badian, Verena Kirn, Peter Mallmann, Stefan Krämer
BACKGROUND/AIM: Sentinel lymph node biopsy (SLNB) has replaced axillary lymph node dissection (ALND) for axillary staging in patients with early-stage breast cancer. The need for therapeutic ALND is the subject of ongoing debate especially after the publication of the ACOSOG Z0011 trial. In a retrospective trial with univariate and multivariate analyses, factors predictive of sentinel lymph node involvement should be analyzed in order to define tumor characteristics of breast cancer patients, where SLNB should not be spared to receive important indicators for adjuvant treatment decisions (e...
June 2018: Anticancer Research
https://www.readbyqxmd.com/read/29789974/a-prospective-feasibility-study-applying-the-acosog-z0011-criteria-to-japanese-patients-with-early-breast-cancer-undergoing-breast-conserving-surgery
#6
Nobuyoshi Kittaka, Ryu Tokui, Chika Ota, Yoko Hashimoto, Kazuyoshi Motomura, Makoto Ishitobi, Takahiro Nakayama, Yasuhiro Tamaki
BACKGROUND: In patients undergoing breast-conserving surgery and having positive sentinel lymph nodes (SLNs), the ACOSOG Z0011 trial showed equivalent loco-regional outcomes for patients receiving SLN dissection (SLND) alone and those receiving axillary lymph node dissection (ALND). We conducted a prospective single-arm study to confirm the applicability of the Z0011 criteria to Japanese patients with breast cancer. METHODS: Patients meeting the Z0011 inclusion criteria and providing consent to receive no additional ALND were prospectively enrolled at the Osaka International Cancer Institute from April 2012 to December 2016...
May 22, 2018: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29788732/the-current-application-of-acosog-z0011-trial-results-is-further-implementation-of-sentinel-lymph-node-intra-operative-histopathological-examination-mandatory-in-breast-cancer-patients-a-single-centre-analysis
#7
T Nowikiewicz, W Zegarski, K Pagacz, M Nowacki, A Morawiec-Sztandera, I Glowacka-Mrotek, M Sowa, M Biedka, A Kolacinska
The main objective of the ACOSOG Z0011 trial was to determine the impact of abandoning complete axillary lymph node dissection (ALND) on survival of breast cancer patients with sentinel node lymph (SLN) metastasis in whom breast conserving therapy (BCT) had been performed. The aim of our study was to assess the clinical value of intra-operative histopathological examination of SLN. Our study comprised 1284 invasive breast cancer patients in whom sentinel lymph node biopsy (SLNB) was carried out. SLN intra-operative histopathological assessment was routinely performed in patients treated within the first period (07...
March 14, 2018: Neoplasma
https://www.readbyqxmd.com/read/29746624/contemporary-evaluation-of-breast-lymph-nodes-in-anatomic-pathology
#8
Beth T Harrison, Jane E Brock
Objectives: Management of the axilla in breast cancer patients has evolved considerably since the introduction of the sentinel lymph node (SLN) biopsy in the 1990s. Several new clinical and technological developments in the last decade warrant special consideration due to their impact on pathology practice. Methods: This review covers the SLN biopsy procedure, issues in the histopathologic and molecular diagnosis of the SLN, and most importantly, evidence from recent practice-changing clinical trials...
May 31, 2018: American Journal of Clinical Pathology
https://www.readbyqxmd.com/read/29661546/strategy-for-the-accurate-preoperative-evaluation-of-the-number-of-metastatic-axillary-lymph-nodes-in-breast-cancer
#9
Nao Imai, Mika Kitayama, Akiko Shibahara, Yuri Bessho, Mai Shibusawa, Aya Noro, Keiko Inakami, Noriko Hanamura, Hiroshi Imai, Tomoko Ogawa
BACKGROUND: After the ACOSOG Z0011 trial, it became important to evaluate the number of metastatic axillary lymph nodes (LNs) preoperatively. The purpose of this paper is to confirm whether the number of metastases can be accurately diagnosed by preoperative computed tomography (CT), ultrasound sonography (US), and US-guided fine-needle aspiration cytology (FNAC). METHODS: We retrospectively analyzed the axillary LNs finding of preoperative CT/US of 470 breast cancer patients...
April 13, 2018: Asian Journal of Surgery
https://www.readbyqxmd.com/read/29580733/the-administration-of-adjuvant-chemo-immuno-therapy-in-the-post-acosog-z0011-era-a-population-based-study
#10
RANDOMIZED CONTROLLED TRIAL
Ingrid G M Poodt, Marjolijn L Rots, Guusje Vugts, Thijs van Dalen, Anne Kuijer, Birgit E P J Vriens, Grard A P Nieuwenhuijzen, Robert-Jan Schipper
PURPOSE: The ACOSOG-Z0011-study has resulted in a trend to a more conservative treatment of the axilla for selected sentinel-node-positive patients. However, axillary nodal involvement has always been an important factor for tumor staging and tailoring adjuvant chemotherapy plans. This study evaluates the impact of omitting completion axillary lymph node dissection (cALND) on the administration of adjuvant chemo (-immuno)therapy in Dutch clinical T1-2N0M0 (cT1-2N0M0) sentinel-node-positive breast cancer patients...
August 2018: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29416374/one-step-nucleic-acid-amplification-the-possible-value-in-assessing-sentinel-lymph-node-metastasis-during-mastectomy
#11
REVIEW
Alison E Hunter-Smith, Zenon Rayter
Breast cancer is the most common cancer in women, worldwide, and 1,400 deaths per day are attributed to it. The success of national screening programs has seen breast cancers being diagnosed at an earlier stage. With conservative surgery to the breast demonstrating equivalent long-term outcomes, the last 10 years have seen a growing interest in the safety of less invasive management for the axilla in breast cancer patients. One-step nucleic acid amplification (OSNA) is a validated, reliable, and efficient tool in identifying micro- and macro-metastases intraoperatively...
2018: Breast Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/29413405/a-quantitative-analysis-of-tumour-characteristics-in-breast-cancer-patients-with-extranodal-extension-in-non-sentinel-nodes
#12
REVIEW
N A O'Keeffe, C O'Neill, A Zahere, V Livingstone, T J Browne, H P Redmond, M A Corrigan
BACKGROUND: The presence of extranodal extension (ENE) is well documented as a predictor of non-sentinel lymph node (NSLN) metastasis. The ACOSOG Z0011 trial (2011) concluded that patients who satisfy criteria including the absence of sentinel lymph node (SLN) ENE can forgo axillary clearance (AC). Currently there are no studies analysing the rate of ENE in NSLN metastasis in which the sentinel node was positive but had no ENE. Determining this incidence will help determine if current paradigms are resulting in residual ENE in NSLN metastasis by forgoing AC based on the Z0011 trial...
April 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29329752/role-of-frozen-section-in-sentinel-lymph-node-biopsy-for-breast-cancer-in-the-era-of-the-acosog-z0011-and-ibcsg-23-10-trials
#13
Augusto Lombardi, Giuseppe Nigri, Stefano Maggi, Gianluca Stanzani, Valeria Vitale, Andrea Vecchione, Alessandro Nania, Claudio Amanti
BACKGROUND: Intraoperative frozen sections (FS) of sentinel lymph nodes (SLN) were evaluated to avoid the need for deferred axillary lymph node dissection (ALND) in patients with early breast cancer (EBC). However, FS has low sensitivity for detecting micro-metastases (<2 mm), resulting in patients who later undergo deferred ALND. The aim of the study was to determine the best clinical approach for selecting patients who would derive real benefit from ALND, as well as to minimize the functional and psychological damage caused by delayed surgery, and the risk of undertreating EBC patients...
August 2018: Surgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
https://www.readbyqxmd.com/read/29279156/the-impact-of-axillary-ultrasound-with-biopsy-in-overtreatment-of-early-breast-cancer
#14
MULTICENTER STUDY
Javier Del Riego, María Jesús Diaz-Ruiz, Milagros Teixidó, Judit Ribé, Mariona Vilagran, Lydia Canales, Melcior Sentís
PURPOSE: (a) To compare the axillary tumor burden detected by fine-needle aspiration cytology (FNAC) versus sentinel lymph node biopsy (SLNB). (b) To evaluate the relationship between axillary tumor burden and the number of suspicious lymph nodes detected by axillary ultrasonography (US). (c) To calculate the false-positive and false-negative rates for FNAC in patients fulfilling ACOSOG Z0011 criteria. METHODS: Retrospective multicenter cross-sectional study of 355 pT1 breast cancers...
January 2018: European Journal of Radiology
https://www.readbyqxmd.com/read/29234253/evaluation-of-sentinel-lymph-node-biopsy-and-axillary-lymph-node-dissection-for-breast-cancer-treatment-concepts-a-retrospective-study-of-1-214-breast-cancer-patients
#15
Roland G Stein, Roland Fricker, Thomas Rink, Hartmut Fitz, Sebastian Blasius, Joachim Diessner, Sebastian F M Häusler, Tanja N Stüber, Victoria Andreas, Achim Wöckel, Thomas Müller
Background: Most breast cancer patients require lumpectomy with axillary sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND). The ACOSOG Z0011-trial failed to detect significant effects of ALND on disease-free and overall survival among patients with limited sentinel lymph node (SLN) metastases. Intense dose-dense chemotherapy and supraclavicular fossa radiation (SFR) are indicated for patients with extensive axillary metastases. In this multicentered study, we investigated the relevance of ALND after positive SLNB to determine adequate adjuvant therapy...
October 2017: Breast Care
https://www.readbyqxmd.com/read/29201278/axillary-nodal-staging-with-contrast-enhanced-ultrasound
#16
REVIEW
Nisha Sharma, Karina Cox
Purpose of Review: Axillary staging in the context of breast cancer is a contentious topic due to the varied practices across UK, Europe, and America. The ACOSOG Z0011 trial has questioned the role of axillary ultrasound in women with breast cancer. Published data has shown that women with ultrasound-positive lymph nodes have a worse prognosis than those with ultrasound-negative lymph nodes. Axillary ultrasound is limited as the sentinel lymph node (SLN) cannot be identified using B-mode ultrasound; however, with the advent of contrast-enhanced ultrasound (CEUS), this has now changed...
2017: Current Breast Cancer Reports
https://www.readbyqxmd.com/read/29100726/expanding-implementation-of-acosog-z0011-in-surgeon-practice
#17
Anna Weiss, Elizabeth A Mittendorf, Sarah M DeSnyder, Rosa F Hwang, Vivian Bea, Isabelle Bedrosian, Karen Hoffman, Beatriz Adrade, Aysegul A Sahin, Henry M Kuerer, Kelly K Hunt, Abigail S Caudle
BACKGROUND: After publication of American College of Surgeons Oncology Group (ACOSOG) Z0011, surgeons at our institution limited axillary surgery to sentinel lymph node dissection (SLND) in 76% of patients meeting trial eligibility criteria. Our study objective was to assess incorporation of the trial data into practice 5 years later. PATIENTS AND METHODS: Patients with clinical T1-2, N0 invasive breast cancer undergoing breast conserving surgery were included. Comparisons were made between patients who underwent axillary lymph node dissection (ALND) and those that had no further surgery...
August 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29033068/treatment-of-the-axila-in-breast-cancer-surgery-systematic-review-of-its-impact-on-survival
#18
REVIEW
Alejandra García Novoa, Benigno Acea Nebril
Sentinel lymph node biopsy and ACOSOG-Z0011 criteria have modified axillary treatment in breast cancer surgery. We performed a systematic review of studies assessing the impact of axillary treatment on survival. The search showed 6891 potentially eligible items. Of them, 23 clinical trials and 12 meta-analyses published between 1980 and 2017 met the study criteria. The review revealed that axillary lymph node dissection (ALND) can be omitted in patients pN0 and pN1mic, without compromising survival. In patients pN1 it is proposed not to treat the axilla or replace ALND for axillary radiotherapy...
November 2017: Cirugía Española
https://www.readbyqxmd.com/read/29031423/the-state-of-surgical-axillary-management-and-adjuvant-radiotherapy-for-early-stage-invasive-breast-cancer-in-the-modern-era
#19
Justin M Mann, Xian Wu, Paul Christos, Himanshu Nagar
BACKGROUND: For clinical T1-2N0 breast cancer, sentinel lymph node biopsy (SLNB) has been shown in American College of Surgeons Oncology Group (ACOSOG) Z0011 to be sufficient for women with 1 to 2 positive sentinel lymph nodes with no added benefit for completion axillary lymph node dissection (ALND). Z0011 specified whole breast radiotherapy (RT) using standard tangential fields; however, later analysis showed variation in field design. We assessed nationwide practice patterns and examined factors associated with patients undergoing completion ALND and subsequent radiation field design...
August 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28970853/development-of-a-nomogram-to-predict-n2-or-n3-stage-in-t1-2-invasive-breast-cancer-patients-with-no-palpable-lymphadenopathy
#20
Isaac Kim, Jai Min Ryu, Jai Myeong Kim, Hee Jun Choi, Se Kyung Lee, Jong Hwan Yu, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam
PURPOSE: Subsequent to the American College of Surgeons Oncology Group (ACOSOG) Z0011 and After Mapping of the Axilla: Radiotherapy or Surgery (AMAROS) trials, complete axillary lymph node dissection is not routinely performed, even in cases where metastatic sentinel lymph nodes are detected. We investigated the percentage of N2 or N3 stages in T1-2 invasive breast cancer patients with no lymphadenopathy and developed a nomogram to predict the possibility of N2 or N3 stages in these patients...
September 2017: Journal of Breast Cancer
keyword
keyword
110600
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"